Interleukin 10 (Tenovil) in the Prevention of Postoperative Recurrence of Crohn's Disease

Overview

Journal Gut

Specialty Gastroenterology

Date 2001 Jun 20

PMID 11413109

Citations 71

Authors

J F Colombel

P Rutgeerts

H Malchow

M Jacyna

O H Nielsen

J Rask-Madsen

S van Deventer

A Ferguson

P Desreumaux

A Forbes

K Geboes

L Melani

M Cohard

Affiliations

Soon will be listed here.

Abstract

Background And Aims: New lesions of Crohn's disease occur early after ileal or ileocolonic resection and ileocolonic anastomosis. We performed a double blind controlled trial to evaluate the safety and tolerance of recombinant human interleukin 10 (IL-10; Tenovil) in subjects operated on for Crohn's disease. We also assessed the effect of Tenovil in preventing endoscopic recurrence 12 weeks after surgery.

Methods: Patients with Crohn's disease who underwent curative ileal or ileocolonic resection and primary anastomosis were randomised within two weeks after surgery to receive subcutaneous Tenovil 4 microg/kg once daily (QD) (n=22) or 8 microg/kg twice weekly (TIW) (n=21), or placebo (QD or TIW) (n=22). An ileocolonoscopy was performed after 12 weeks of treatment.

Results: Compliance was excellent. The most frequently observed adverse events were mild and moderate in severity and equally distributed across treatment groups. Thirty seven patients in the pooled Tenovil group and 21 patients in the pooled placebo group were evaluable by endoscopy. At 12 weeks, 11 of 21 patients (52%) in the placebo group had recurrent lesions compared with 17 of 37 patients (46%) in the Tenovil group (ns). The incidence of severe endoscopic recurrence was similar in both groups (9%).

Conclusion: Tenovil treatment for 12 consecutive weeks in patients with Crohn's disease after intestinal resection was safe and well tolerated. No evidence of prevention of endoscopic recurrence of Crohn's disease by Tenovil was observed.

Citing Articles

Sonic vibration ameliorates inflammatory diseases via the up-regulation of IL-10.

Ahn H, Jung E, Cho M, Shin M, Choi J, Lee G Anim Cells Syst (Seoul). 2024; 28(1):161-170.

PMID: 38686362 PMC: 11057401. DOI: 10.1080/19768354.2024.2346598.

Engineering cytokine therapeutics.

Deckers J, Anbergen T, Hokke A, de Dreu A, Schrijver D, de Bruin K Nat Rev Bioeng. 2023; 1(4):286-303.

PMID: 37064653 PMC: 9933837. DOI: 10.1038/s44222-023-00030-y.

An Engineered Probiotic Produces a Type III Interferon IFNL1 and Reduces Inflammations in Inflammatory Bowel Disease Models.

Chua K, Ling H, Hwang I, Lee H, March J, Lee Y ACS Biomater Sci Eng. 2022; 9(9):5123-5135.

PMID: 36399014 PMC: 10498420. DOI: 10.1021/acsbiomaterials.2c00202.

Early Post-Operative Endoscopy Is Associated with Lower Surgical Recurrence of Crohn's Disease: A Retrospective Study of Three Successive Cohorts.

Amicone C, Marques C, Reenaers C, Van Kemseke C, Seidel L, Louis E Gastroenterol Res Pract. 2022; 2022:6341069.

PMID: 36388633 PMC: 9643063. DOI: 10.1155/2022/6341069.

Inflammatory Bowel Disease: A Review of Pre-Clinical Murine Models of Human Disease.

Katsandegwaza B, Horsnell W, Smith K Int J Mol Sci. 2022; 23(16).

PMID: 36012618 PMC: 9409205. DOI: 10.3390/ijms23169344.

References

Lochs H, Mayer M, Fleig W, Mortensen P, Bauer P, Genser D . Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology. 2000; 118(2):264-73. DOI: 10.1016/s0016-5085(00)70208-3. View

dHaens G, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P . Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998; 114(2):262-7. DOI: 10.1016/s0016-5085(98)70476-7. View

Rutgeerts P, Geboes K, VANTRAPPEN G, KERREMANS R, Coenegrachts J, Coremans G . Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut. 1984; 25(6):665-72. PMC: 1432363. DOI: 10.1136/gut.25.6.665. View

Fiocchi C . Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998; 115(1):182-205. DOI: 10.1016/s0016-5085(98)70381-6. View

Lautenbach E, Berlin J, Lichtenstein G . Risk factors for early postoperative recurrence of Crohn's disease. Gastroenterology. 1998; 115(2):259-67. DOI: 10.1016/s0016-5085(98)70191-x. View

Herfarth H, Bocker U, Janardhanam R, Sartor R . Subtherapeutic corticosteroids potentiate the ability of interleukin 10 to prevent chronic inflammation in rats. Gastroenterology. 1998; 115(4):856-65. DOI: 10.1016/s0016-5085(98)70257-4. View

MacDonald T . Effector and regulatory lymphoid cells and cytokines in mucosal sites. Curr Top Microbiol Immunol. 1999; 236:113-35. DOI: 10.1007/978-3-642-59951-4_7. View

Hellers G, Cortot A, Jewell D, Leijonmarck C, Lofberg R, Malchow H . Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group. Gastroenterology. 1999; 116(2):294-300. DOI: 10.1016/s0016-5085(99)70125-3. View

Rutgeerts P, Geboes K, VANTRAPPEN G, Beyls J, KERREMANS R, Hiele M . Predictability of the postoperative course of Crohn's disease. Gastroenterology. 1990; 99(4):956-63. DOI: 10.1016/0016-5085(90)90613-6. View

10.

de Waal Malefyt R, Abrams J, Bennett B, Figdor C, De Vries J . Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med. 1991; 174(5):1209-20. PMC: 2119001. DOI: 10.1084/jem.174.5.1209. View

11.

Caprilli R, Andreoli A, Capurso L, Corrao G, DAlbasio G, Gioieni A . Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Aliment Pharmacol Ther. 1994; 8(1):35-43. DOI: 10.1111/j.1365-2036.1994.tb00158.x. View

12.

Brignola C, Cottone M, Pera A, Ardizzone S, Scribano M, de Franchis R . Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology. 1995; 108(2):345-9. DOI: 10.1016/0016-5085(95)90059-4. View

13.

Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R . Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology. 1995; 108(6):1617-21. DOI: 10.1016/0016-5085(95)90121-3. View

14.

McLeod R, Wolff B, Steinhart A, Carryer P, ORourke K, ANDREWS D . Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology. 1995; 109(2):404-13. DOI: 10.1016/0016-5085(95)90327-5. View

15.

Niessner M, Volk B . Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin Exp Immunol. 1995; 101(3):428-35. PMC: 1553229. DOI: 10.1111/j.1365-2249.1995.tb03130.x. View

16.

Dubucquoi S, Janin A, Klein O, Desreumaux P, Quandalle P, Cortot A . Activated eosinophils and interleukin 5 expression in early recurrence of Crohn's disease. Gut. 1995; 37(2):242-6. PMC: 1382725. DOI: 10.1136/gut.37.2.242. View

17.

Florent C, Cortot A, Quandale P, Sahmound T, Modigliani R, Sarfaty E . Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). Eur J Gastroenterol Hepatol. 1996; 8(3):229-33. DOI: 10.1097/00042737-199603000-00008. View

18.

Herfarth H, Mohanty S, Rath H, Tonkonogy S, Sartor R . Interleukin 10 suppresses experimental chronic, granulomatous inflammation induced by bacterial cell wall polymers. Gut. 1996; 39(6):836-45. PMC: 1383456. DOI: 10.1136/gut.39.6.836. View

19.

Pretolani M, Goldman M . IL-10: a potential therapy for allergic inflammation?. Immunol Today. 1997; 18(6):277-80. DOI: 10.1016/s0167-5699(97)80023-0. View

20.

Desreumaux P, Brandt E, Gambiez L, Emilie D, Geboes K, Klein O . Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. Gastroenterology. 1997; 113(1):118-26. DOI: 10.1016/s0016-5085(97)70116-1. View